专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050059654A1 Method for treatment of depression and anxiety disorders by combination therapy 审中-公开
标题翻译：通过联合治疗治疗抑郁症和焦虑症的方法
公开(公告)号：US20050059654A1
公开(公告)日：2005-03-17
申请号：US10935826
申请日：2004-09-08
申请人： Stephen Arneric , Cathryn Clary , Douglas Feltner , Wilma Harrison , Richard Kavoussi , Atul Pande , Charles Taylor
发明人： Stephen Arneric , Cathryn Clary , Douglas Feltner , Wilma Harrison , Richard Kavoussi , Atul Pande , Charles Taylor
IPC分类号： A61K31/135 , A61K31/137 , A61K31/195 , A61K31/197 , A61K31/519 , A61K31/5375 , A61K45/06 , A61P25/22 , A61P25/24
CPC分类号： A61K31/195 , A61K31/135 , A61K31/137 , A61K31/197 , A61K31/519 , A61K31/5375 , A61K45/06 , A61K2300/00
摘要： A method is provided of treating depression in mammals, including a human, as well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal in effective amount a combination of active ingredients comprising a) an alpha-2delta (A2D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and, active agents selected from; (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective noradrenaline re-uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c). A pharmaceutical composition comprising a therapeutically effective amount (a) an A2D ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from; (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNRI or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c) is also provided. Preferred active ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.
摘要翻译：提供了一种治疗包括人在内的哺乳动物的抑郁症的方法，以及抑郁症和伴随的疾病，病症或病症，例如但不限于焦虑症，睡眠障碍和创伤后应激障碍。所述方法包括给予哺乳动物有效量的活性成分的组合，其包含a）α-2delta（A2D）配体或其前药，或所述A2D配体或所述前药的药学上可接受的盐，和选自以下的活性剂：（b）选择性5-羟色胺再摄取抑制剂（SSRI）或其前药或所述SSRI或所述前药的药学上可接受的盐，（c）选择性去甲肾上腺素再摄取抑制剂（SNRI）或其前药或药学上可接受的所述SNRI的盐或所述前药以及（b）和（c）的混合物。一种药物组合物，其包含治疗有效量的（a）A2D配体或其前药，或所述A2D配体或所述前药的药学上可接受的盐和选自以下的活性剂：（b）所述SSRI或所述前药的SSRI或其前药或药学上可接受的盐，（c）所述SNRI或所述前药的SNRI或其前药或其药学上可接受的盐，和（b）和（c ）。用于治疗和药物组合物的优选活性成分包括普瑞巴林，加巴喷丁，舍曲林和瑞波西汀。

IPRDB

热门服务

关于我们

友情链接

联系方式